These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28342452)

  • 1. Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer.
    Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Robles AI; Faus-Dáder MJ; Calleja-Hernández MÁ
    Mutat Res Rev Mutat Res; 2017; 771():32-58. PubMed ID: 28342452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.
    Pérez-Ramírez C; Cañadas-Garre M; Alnatsha A; Villar E; Delgado JR; Faus-Dáder MJ; Calleja-Hernández MŸ
    Pharmacol Res; 2016 Sep; 111():877-884. PubMed ID: 27498158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
    Yang Y; Xian L
    Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
    Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies.
    Qin Q; Zhang C; Yang X; Zhu H; Yang B; Cai J; Cheng H; Ma J; Lu J; Zhan L; Liu J; Liu Z; Xu L; Sun X
    PLoS One; 2013; 8(11):e79864. PubMed ID: 24260311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.
    Yin M; Yan J; Voutsina A; Tibaldi C; Christiani DC; Heist RS; Rosell R; Booton R; Wei Q
    Lung Cancer; 2011 Jun; 72(3):370-7. PubMed ID: 21075476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer: A Network Meta-Analysis.
    Yu SN; Liu GF; Li XF; Fu BH; Dong LX; Zhang SH
    J Cell Biochem; 2017 Dec; 118(12):4782-4791. PubMed ID: 28520216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
    Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.
    Tan LM; Qiu CF; Zhu T; Jin YX; Li X; Yin JY; Zhang W; Zhou HH; Liu ZQ
    Sci Rep; 2017 Jul; 7(1):5593. PubMed ID: 28717179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer].
    Xu C; Wang X; Zhang Y; Li L
    Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):912-7. PubMed ID: 22152690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.
    He C; Duan Z; Li P; Xu Q; Yuan Y
    Anticancer Drugs; 2013 Mar; 24(3):300-5. PubMed ID: 23211354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
    Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
    Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy.
    Li D; Zhou Q; Liu Y; Yang Y; Li Q
    Med Oncol; 2012 Sep; 29(3):1622-8. PubMed ID: 21805378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A
    Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement.
    Li DJ; Xiao D
    BMC Cancer; 2017 Jul; 17(1):501. PubMed ID: 28743242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy.
    Yuan P; Liu L; Wu C; Zhong R; Yu D; Wu J; Xu Y; Nie S; Miao X; Sun Y; Xu B; Lin D
    Cancer Biol Ther; 2010 Nov; 10(9):854-9. PubMed ID: 20814250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients.
    Yu D; Shi J; Sun T; Du X; Liu L; Zhang X; Lu C; Tang X; Li M; Xiao L; Zhang Z; Yuan Q; Yang M
    Tumour Biol; 2012 Jun; 33(3):877-84. PubMed ID: 22249976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
    Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
    Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.